Drg2, or developmentally regulated GTP-binding protein 2, is a GTP-binding protein involved in multiple cellular functions. It is crucial in pathways related to cell growth, inflammation, and microtubule dynamics, which are essential for normal cell function and development. Genetic models, such as knockout (KO) mice, have been instrumental in studying Drg2's function.

DRG2 deficiency in endothelial cells promotes senescence and vascular endothelial dysfunction, as DRG2 KO mice show reduced cerebral blood flow and lung blood vessel density, along with decreased angiogenic capability of endothelial cells [1]. In macrophages, DRG2 is crucial for the initial inflammatory response against Listeria monocytogenes infection, as both whole-body and macrophage-specific DRG2 KO mice have low IL-6 levels during early infection and increased susceptibility to the infection [2]. In melanoma, DRG2 is required for the growth of primary tumors and metastases, and its inhibition suppresses VEGF-A expression [3]. In the brain, DRG2 KO mice display impaired motor behaviors with reduced striatal dopamine release [4].

In conclusion, Drg2 is a key regulator in multiple biological processes. The use of Drg2 KO mouse models has revealed its importance in vascular function, immune response, tumor growth, and neurological function. Understanding Drg2's function provides insights into the mechanisms of related diseases, potentially guiding the development of new therapeutic strategies.